Clarametyx Biosciences Inc. develops immune-enabling biologic therapies that target biofilms, the protective barriers surrounding bacteria, to combat life-threatening infections. Their technology aims to reduce antibiotic resistance by providing an alternative approach to traditional antibiotic treatments.

DIANT Pharma develops continuous processing technology using proprietary DIANT® Jet systems for the scalable production of lipid and polymer-based nanoparticles. This technology enhances the uniformity and quality of nanoparticle drug products and vaccines while reducing manufacturing risks and accelerating time to market.

Endolytix develops novel therapeutics targeting highly resistant mycobacterial infections that are difficult to treat with current antibiotics. Their approach utilizes targeted drug delivery vehicles to administer bactericidal payloads effectively inside and outside of host macrophages. This strategy overcomes the complex cell envelope defenses that typically block conventional drug access to pathogenic NTM.

The startup develops microbiome-modulating drugs that restore microbial diversity to prevent bacterial infections in patients with serious medical needs. Their tailored high-diversity therapeutics enhance the microbiome's resilience, enabling effective prevention and treatment of debilitating infections and diseases.

Inceptor Bio is developing OUTLAST™ CAR T cell therapies that reprogram T cells to maintain a stem-like, durable anti-tumor phenotype, enhancing their effectiveness against solid tumors. This approach addresses the challenge of T cell exhaustion and immune suppression in aggressive cancer environments, aiming to improve patient outcomes through sustained therapeutic activity.

Kincell Bio is a contract development and manufacturing organization that provides end‑to‑end cell therapy services, including analytical development, process development, and GMP‑compliant manufacturing. It helps biotech and pharma companies move therapies from early clinical stages through pivotal trials to commercial supply with tailored, expert‑driven strategies and rigorous quality testing.

neuro42 develops portable magnetic resonance imaging (MRI) machines that integrate artificial intelligence and robotics for real-time imaging and guidance during neurological procedures. This technology enables rapid diagnosis and targeted interventions for conditions such as stroke, tumors, and epilepsy, improving patient outcomes by facilitating immediate imaging in critical care settings.

Promaxo has developed a compact, office-based MRI system specifically designed for guiding targeted prostate biopsies and cancer treatments, achieving a 77% cancer detection rate. This technology enables earlier identification of aggressive prostate cancer, allowing for timely interventions without the need for major facility upgrades.

RA UNLIMITED harnesses solar photovoltaic technology to generate clean and affordable electricity for homes, businesses, and communities in the Philippines. The company addresses the reliance on fossil fuels by providing sustainable energy solutions that create jobs and enhance the quality of life for Filipinos.

The startup develops a cell and gene therapy platform that utilizes M83-based CAR-T cells, which are engineered to resist exhaustion and enhance metabolism in the tumor microenvironment. This technology enables researchers to create more effective T cell-based therapeutics and gene therapies aimed at curing cancer.